Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and ...

Moreover, 15% of them were taking LAMA or LABA therapies in combination ... approval and launch of the company's lead drug candidate into the large COPD market in late 2023 or 2024.

The CRYSTAL study is the first LABA/LAMA pragmatic ... from other COPD treatments, such as inhaled steroid-containing combination therapies," said Vasant Narasimhan, Global Head Drug Development ...

A new study published in the CHEST journal found that ensifentrine, an innovative inhaled therapy, significantly reduces the ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...

Also in November 2024, the Company completed enrollment in a Phase 2 dose-ranging trial with glycopyrrolate, a LAMA ... of our drug Ohtuvayre to treat adult patients in the US with COPD ...

Also in November 2024, the Company completed enrollment in a Phase 2 dose-ranging trial with glycopyrrolate, a LAMA ... of our drug Ohtuvayre to treat adult patients in the US with COPD ...

Among the drug subgroups, ACL was associated with significant (P ... “Overall, these findings support the use of LAMA in elderly COPD patients and underscore the need for tailored treatment strategies ...